Informazione Scientifica & Salute

Cancer immunotherapy may increase risk of developing rheumatologic disorders: Johns Hopkins study

Sh@wn — Sun, 26 Jun 2016 11:23:19 GMT

Johns Hopkins University researchers have found a link between cancer immunotherapy drugs and an increased risk of developing rheumatologic disorders—that they expect to only be exacerbated as their use increases. They conducted what’s thought to be the largest published study of patients taking immunotherapies aimed at examining the potential connection between the drug class and these sorts of diseases.

Amgen, Inc. Fits Into Pfizer’s Restructuring Plans Perfectly

Sh@wn — Sun, 26 Jun 2016 11:12:58 GMT

Pfizer Inc. (NYSE:PFE) is currently considering acting on its plans to reorganize. The drugmaker announced that it would be restructuring itself to focus entirely on some of the key growth businesses, while trimming some of the units.

Novartis aims to nearly triple biosimilar drugs on market by 2020

Sh@wn — Mon, 20 Jun 2016 21:31:33 GMT

Switzerland's Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals' profits.

Oral JAK Inhibitor Promising in Ankylosing Spondylitis

Sh@wn — Fri, 10 Jun 2016 22:21:17 GMT

The oral Janus kinase (JAK) inhibitor tofacitinib (Xeljanz, Pfizer) might be a new option for patients with ankylosing spondylitis, according to results from a new phase 2 study.

Novartis plans head-to-head trial for Cosentyx and Humira

Sh@wn — Fri, 10 Jun 2016 08:58:49 GMT

Novartis and Sandoz are to present new analyses indicating that their biologic Cosentyx could lead to higher responses than AbbVie's anti-inflammatory super-blockbuster Humira in improving the signs and symptoms of ankylosing spondylitis and psoriatic arthritis.

Bet You Can't Guess Which of These 10 Big Pharma Names Has the Largest Late-Stage Pipeline

Sh@wn — Mon, 30 May 2016 19:04:26 GMT

Phase 3 data is the bread and butter of all drugmaker catalysts. Find out which Big Pharma stock has a surprisingly large late-stage pipeline.

Samsung Bioepis notches European Commission nod for Remicade biosim

Sh@wn — Mon, 30 May 2016 18:57:45 GMT

Incheon-based Samsung Bioepis has won approval from the European Commission for its biosimilar of Remicade, marking its second anti-TNF-α therapy in the region.

Sandoz’ MabThera biosimilar to get EU review

Sh@wn — Thu, 26 May 2016 15:19:27 GMT

European regulators have agreed to review Sandoz' biosimilar to Roche's oncology/immunology blockbuster rituximab.

Janssen’s Stelara impresses in Crohn’s maintenance trial

Sh@wn — Thu, 26 May 2016 15:17:19 GMT

Janssen's biologic Stelara has hit targets in a Phase III trial testing its ability to maintain clinical remission in patients with Crohn's disease.

Novartis' Ilaris awarded three breakthrough badges in the US

Sh@wn — Wed, 27 Apr 2016 11:44:47 GMT

Novartis’ Ilaris has picked up three breakthrough designations in the US for potential indications spanning a group of auto inflammatory disorders called Periodic Fever Syndromes or Hereditary Periodic Fevers.